CTRI/2012/08/002895CompletedPhase 4
Assessment of efficacy and safety of desvenlafaxine versus escitalopram in major depressive disorder with symptoms of anxiety:a randomized clinical trial
Department of Pharmacology IPGMER Kolkata0 sites85 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Enrollment
- 85
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •subjects of major depressive disorder with symptoms of anxiety with HAM score of seven to eighteen
- •baseline HAMA score more than or equal to twelve
- •Subjects must be willing to give written informed consent
Exclusion Criteria
- •subjects with age less tha eighteen or more than sixty
- •Pregnant and lactating women
- •Baseline HAMD score less than seven or more than eighteen
- •Baseline HAMA score less than 12
- •Subjects with psychotic features
- •Subjects with suicidality catatonic features
- •Subjects on any antidepressant medications in the last two months
- •Subjects with concurrent severe medical disorders like uncontrolled diabetes hypertension ischemic heart disease chronic renal failure cirrhosis any malignancy etc
- •Subjects with history of substance abuse in the last two years
- •Subjects with mixed depression and anxiety disorder or any other episodes of other mood disorder bipolar disorder dysthymia etc
- •Subjects with any other psychiatric disorders
- •Subjects on other concurrent medications known to have drug interact with the study medications like other SSRI SNRI tricyclic antidepressants etc
- •Subjects with past history of anaphylaxis or hypersensitivity to any of the study medications
Investigators
Similar Trials
Completed
Phase 2
effectiveness of Venlafaxine and Duloxetine on peripheral neuropathy caused by chemotherapypripheral neuropathy.Drug-induced polyneuropathyIRCT2015060922632N1Vice chancellor for research, Kermanshah University of Medical Sciences156
Not yet recruiting
Phase 2
Compareing effects of venlafaxine and Placebo on depression, withdrawal symptoms, cravingAddiction.Mental and behavioral disorders due to use of other stimulants, including caffeine: dependence syndromesIRCT20160717028967N8Kermanshah University of Medical Sciences66
Completed
Phase 3
Study Evaluating DVS-233 SR to Treat Vasomotor Systems Associated With MenopauseHot FlashesSleep DisordersMenopauseNCT00256685Wyeth is now a wholly owned subsidiary of Pfizer568
Not yet recruiting
Phase 4
To know the Efficacy of the drugs Deflazacort and Tamsulosin in Kidney stone Clearance after Stone Breakage by Shock method.CTRI/2021/08/035475SRM Medical College Hospital and Research Institue
Completed
Phase 3
Study of Desvenlafaxine in Treating Major Depressive Disorder.Major Depressive DisorderNCT04364997CSPC ZhongQi Pharmaceutical Technology Co., Ltd.420